Long-Term Anatomical and Functional Survival of Boston Type 1 Keratoprosthesis in Congenital Aniridia

Purpose: To analyze the long-term anatomical survival, functional survival, and complications of Boston type 1 keratoprosthesis (KPro) in the eyes with congenital aniridia-associated keratopathy (AAK). Methods: A retrospective review of 12 eyes with congenital aniridia that underwent a Boston type 1 KPro surgery was conducted. A Kaplan–Meier analysis was performed. Anatomical and functional success criteria were KPro retention and a best corrected visual acuity (BCVA) ≤1.3 LogMAR (≥0.05 decimal) at the end of a follow-up period. Postoperative complications were recorded. Results: The mean preoperative BCVA was 2.1 ± 0.9 (range: 3.8–1) LogMAR, and glaucoma was a comorbidity in all the cases. Five years after the surgery, the overall retention rate was 10/12 (83.3%), and 50% had functional success. Only three (25%) of the 12 cases did not achieve a BCVA ≤1.3 LogMAR. The cumulative probability of anatomical success was 92, 79, and 79% after 1, 5, and 10 years, respectively. The cumulative probability of functional success was 57 and 46% after 1 and 5 years, respectively. The mean anatomical and functional survival time was 10 ± 1.3 (95% IC = 7.5–12.3 years) and 3.8 ± 0.9 years (95% IC = 1.8–5.8 years), respectively. The most common postoperative complication was retroprosthetic membrane (RPM) formation in 8/16 cases (66%). The mean number of complications per case was 2.4 ± 1.8 (0–6). Conclusions: The Boston type 1 KPro is a viable option for patients with AAK with good anatomical and functional long-term results. Glaucoma is an important preoperative condition that affects functional results. Retroprosthetic membrane formation seems to have a higher incidence in this condition.

[1]  A. Soldevila,et al.  Transmucosal Boston Keratoprosthesis Type I in a Patient With Advanced Ocular Cicatricial Pemphigoid. , 2020, Cornea.

[2]  J. Sugar,et al.  Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center. , 2019, American journal of ophthalmology.

[3]  G. Grabner,et al.  Osteo-odonto-, Tibial bone and Boston keratoprosthesis in clinically comparable cases of chemical injury and autoimmune disease. , 2019, The ocular surface.

[4]  N. Subramanian,et al.  Keratoprosthesis: Current global scenario and a broad Indian perspective , 2018, Indian journal of ophthalmology.

[5]  M. S. Cortina,et al.  Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study , 2018, PloS one.

[6]  E. Holland,et al.  Intermediate-Term and Long-Term Outcomes With the Boston Type 1 Keratoprosthesis in Aniridia , 2018, Cornea.

[7]  J. Chodosh,et al.  Long-term Visual Outcomes and Complications of Boston Keratoprosthesis Type II Implantation. , 2017, Ophthalmology.

[8]  B. Chauhan,et al.  Congenital aniridia: etiology, manifestations and management , 2016, Expert review of ophthalmology.

[9]  M. Belin,et al.  Suggested Guidelines for Reporting Keratoprosthesis Results: Consensus Opinion of the Cornea Society, Asia Cornea Society, EuCornea, PanCornea, and the KPRO Study Group , 2016, Cornea.

[10]  M. Harissi-Dagher,et al.  Outcomes following Boston type 1 keratoprosthesis implantation in aniridia patients at the University of Montreal. , 2014, American journal of ophthalmology.

[11]  P. Song,et al.  CLINICAL OUTCOMES? , 2014 .

[12]  K. Goins,et al.  Treatment of Aniridia With Boston Type I Keratoprosthesis , 2013, Cornea.

[13]  E. Holland,et al.  Surgical and visual outcomes of the type I Boston Keratoprosthesis for the management of aniridic fibrosis syndrome in congenital aniridia. , 2012, American journal of ophthalmology.

[14]  M. Belin,et al.  Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis type 1: multicenter study results. , 2012, Ophthalmology.

[15]  J. Chodosh,et al.  Titanium back plate for a PMMA keratoprosthesis: clinical outcomes , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.

[16]  D. Hu,et al.  Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. , 2008, American journal of ophthalmology.

[17]  R. Pineda,et al.  Outcomes of Boston keratoprosthesis in aniridia: a retrospective multicenter study. , 2007, American journal of ophthalmology.